Correction to: International Journal of Obesity 2013; 37: 1443–1451; doi:10.1038/ijo.2013.120
Further to erratum: IJO.2013.148 there is also an error on page 1448, Table 3, as outlined below:
-
In column 1, the second subheading under ‘Co-primary end points’ should read ‘Proportion maintaining ⩾5% run-in weight loss’ (not >5%).
-
In column 1, the third subheading under ‘Co-primary end points’ should read ‘Proportion with ⩾5% weight loss’ (not >5%).
The publisher apologises for this error.
Author information
Consortia
Additional information
The online version of the original article can be found at 10.1038/ijo.2013.120
Rights and permissions
About this article
Cite this article
Wadden, T., Hollander, P., Klein, S. et al. Erratum: Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes 39, 187 (2015). https://doi.org/10.1038/ijo.2014.88
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijo.2014.88
This article is cited by
-
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Drugs (2024)
-
Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial
Cardiovascular Diabetology (2019)
-
Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington’s Disease
Scientific Reports (2018)
-
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Current Obesity Reports (2018)
